Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

SOC Role of Frontline Nivolumab Plus Cabozantinib in Metastatic RCC Confirmed With Long-Term Efficacy Results

February 5th 2024

Frontline nivolumab plus cabozantinib continued to demonstrate long-term efficacy and safety vs sunitinib in patients with untreated RCC.

Dr McGregor on Sacituzumab Govitecan Plus Enfortumab Vedotin in Treatment-Resistant mUC

February 5th 2024

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in Untreated RCC

February 2nd 2024

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor Size in RCC

February 2nd 2024

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

Dr Arner on the Role of SETD2 Loss in Tumor Growth and Metastasis in ccRCC

February 1st 2024

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

Dr Garmezy on the Impact of Combination Regimens on Outcomes and Quality of Life in Patients With RCC

February 1st 2024

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Garmezy Highlights Ongoing and Future Research Directions Across RCC Subtypes

January 31st 2024

Benjamin Garmezy, MD, provides an overview of recent data on immuno-oncology/TKI combination data in variant renal cell carcinoma.

The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma

January 30th 2024

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-Up Data From the Phase 3 CheckMate 214 Trial

January 30th 2024

Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).

Dr Basu on the Potential Utility of MRD-Guided Adjuvant Therapy in RCC

January 29th 2024

Arnab Basu, MD, MPH, FACP, discusses the phase 2 MRD Gate RCC trial of molecular residual disease–guided adjuvant therapy in in renal cell carcinoma.

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC

January 28th 2024

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

January 27th 2024

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

January 27th 2024

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

January 27th 2024

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

January 27th 2024

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

January 27th 2024

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

January 27th 2024

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC

January 27th 2024

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

January 25th 2024

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies

January 24th 2024

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.